Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680438 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| Hydrochloric Acid SCHEMBL5008498 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| Hydrochloric Acid SCHEMBL28905020 | 0.98 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| Biphenyl SCHEMBL21043711 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| SCHEMBL28755796 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| SCHEMBL950218 | 0.83 | LMNA (0.73) | SMN1; SMN2LMNAPOLBNPC1L3MBTL1 | |
| SCHEMBL30475735 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPARP1POLBNPC1 | |
| SCHEMBL17180592 | 0.81 | LMNA (0.70) | SMN1; SMN2LMNAPOLBNPC1L3MBTL1 | |
| SCHEMBL580815 | 0.81 | LMNA (0.59) | SMN1; SMN2LMNAPARP1RAB9APOLB | |
| SCHEMBL105459 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAPOLBNPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094660-A | Composition in the form of an oil-in-water emulsion | — | 2026-05-26 | — | — | CN | claimed |
| EP-4687829-A1 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-02-11 | — | — | EP | claimed |
| US-20250381116-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | OREAL (FR) | 2025-12-18 | — | — | US | claimed |
| US-20250161201-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2025-05-22 | — | — | US | claimed |
| WO-2025091220-A2 | COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION | L'OREAL (FR) | 2025-05-08 | — | — | WO | claimed |
| WO-2025091239-A1 | COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION | L'OREAL (FR) | 2025-05-08 | — | — | WO | claimed |
| EP-4543408-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | L'OREAL (FR) | 2025-04-30 | — | — | EP | claimed |
| CN-119654151-A | Composition for caring skin | 莱雅公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119630382-A | Solubilization of thiopyridone compounds and compositions containing same | 莱雅公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119462424-A | 2-Cyano-5-dimethylamino-2, 4-pentadiene amide compound and application thereof | 郑州手性药物研究院有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2002069916-A2 | ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-09-12 | — | — | WO | claimed |
| US-6383476-B1 | Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent | THE PROCTER & GAMBLE COMPANY | 2002-05-07 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| US-6028111-A | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents | OXIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0331052-A2 | Process for the preparation of imidized acrylic polymers | ELF ATOCHEM ITALIA S.r.l. (IT) | 1989-09-06 | — | — | EP | claimed |
| EP-0315151-A2 | Process for the preparation of imidized acrylic polymers | ELF ATOCHEM ITALIA S.r.l. (IT) | 1989-05-10 | — | — | EP | claimed |
| US-4080336-A | Process for the production of 2-chloronicotinic acid amide | LONZA LTD. (CH) | 1978-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161201-A1 | COSMETIC COMPOSITION | CYP19A1, SHBG, HSD17B11 | SMN1; SMN2 4266/4885LMNA 3019/4885PARP1 4749/4885 |
| US-20250381116-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | TBCB, CCNB3, CYP24A1 | SMN1; SMN2 2297/4885LMNA 3917/4885PARP1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.